No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — claims suc­cess af­ter all

A set­back in Covid-19 didn’t stop No­var­tis from team­ing up with Mol­e­c­u­lar Part­ners again. And this time, they will be look­ing for ra­dio­phar­ma­ceu­ti­cals.

Hav­ing bet …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER